Abstract: Traumatic brain injury (TBI) is a mechanical injury to the brain, which can be sustained due to falls, accidents, contact sports or in combat situation. It is a serious health problem-affecting people of all ages worldwide. As per the recent epidemiological study, more than 55 million people suffer from TBI annually (GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators, 2019), and its prevalence has increased by almost 8.4% between 1990 and 2016 (GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators, 2019). Depending on severity, TBI can lead to premature death and disability. In long-term survivors, it is also a major risk factor for development of neurodegenerative diseases like Alzheimer’s disease or Parkinson’s disease (Smith et al., 2013). All together TBI causes immense emotional distress and brings huge financial burden not only to the patients and family members but also to the society (GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators, 2019). Unfortunately, there is no effective pharmacological treatment available for TBI. Current therapeutic approaches are primarily focused on minimizing or alleviating injury-inflicted symptoms but do not restrict injury-induced brain damage. Thus, there is an urgent need to identify and develop pharmacological agents that can improve TBI outcomes and prevent neurodegeneration.